Edwards Lifesciences raises FY26 guidance following strong Q1
Edwards Lifesciences has lifted its full-year 2026 growth outlook to between 9% and 11%, up from 8% to 10% previously, due to ‘better than expected’ performance in Q1. The medtech giant reported revenues of around $1.65bn in Q1, driven by…











